Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
Abstract Lung cancer is the leading cause of cancer mortality. As a heterogeneous disease, it has different subtypes and various treatment modalities. In addition to conventional surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have also been applied in the clinics. However...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | Cancer Nanotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12645-023-00174-x |
| _version_ | 1797854080564985856 |
|---|---|
| author | Yifan Liu Wenxu Cheng HongYi Xin Ran Liu Qinqi Wang Wenqi Cai Xiaochun Peng Fuyuan Yang HongWu Xin |
| author_facet | Yifan Liu Wenxu Cheng HongYi Xin Ran Liu Qinqi Wang Wenqi Cai Xiaochun Peng Fuyuan Yang HongWu Xin |
| author_sort | Yifan Liu |
| collection | DOAJ |
| description | Abstract Lung cancer is the leading cause of cancer mortality. As a heterogeneous disease, it has different subtypes and various treatment modalities. In addition to conventional surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have also been applied in the clinics. However, drug resistance and systemic toxicity still cannot be avoided. Based on the unique properties of nanoparticles, it provides a new idea for lung cancer therapy, especially for targeted immunotherapy. When nanoparticles are used as carriers of drugs with special physical properties, the nanodrug delivery system ensures the accuracy of targeting and the stability of drugs while increasing the permeability and the aggregation of drugs in tumor tissues, showing good anti-tumor effects. This review introduces the properties of various nanoparticles including polymer nanoparticles, liposome nanoparticles, quantum dots, dendrimers, and gold nanoparticles and their applications in tumor tissues. In addition, the specific application of nanoparticle-based drug delivery for lung cancer therapy in preclinical studies and clinical trials is discussed. |
| first_indexed | 2024-04-09T20:00:09Z |
| format | Article |
| id | doaj.art-c949e63429b9425ab6b179861ff7adc7 |
| institution | Directory Open Access Journal |
| issn | 1868-6958 1868-6966 |
| language | English |
| last_indexed | 2024-04-09T20:00:09Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Nanotechnology |
| spelling | doaj.art-c949e63429b9425ab6b179861ff7adc72023-04-03T05:16:31ZengBMCCancer Nanotechnology1868-69581868-69662023-03-0114112510.1186/s12645-023-00174-xNanoparticles advanced from preclinical studies to clinical trials for lung cancer therapyYifan Liu0Wenxu Cheng1HongYi Xin2Ran Liu3Qinqi Wang4Wenqi Cai5Xiaochun Peng6Fuyuan Yang7HongWu Xin8Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze UniversityJingzhou Hospital Affiliated to Yangtze University, Yangtze UniversityThe Doctoral Scientific Research Center, People’s Hospital of LianjiangLaboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze UniversityLaboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze UniversityXinzhou Traditional Chinese Medicine Hospital, Zhongnan Hospital of Wuhan University (Xinzhou)Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze UniversityDepartment of Physiology, School of Basic Medicine, Health Science Center, Yangtze UniversityLaboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze UniversityAbstract Lung cancer is the leading cause of cancer mortality. As a heterogeneous disease, it has different subtypes and various treatment modalities. In addition to conventional surgery, radiotherapy and chemotherapy, targeted therapy and immunotherapy have also been applied in the clinics. However, drug resistance and systemic toxicity still cannot be avoided. Based on the unique properties of nanoparticles, it provides a new idea for lung cancer therapy, especially for targeted immunotherapy. When nanoparticles are used as carriers of drugs with special physical properties, the nanodrug delivery system ensures the accuracy of targeting and the stability of drugs while increasing the permeability and the aggregation of drugs in tumor tissues, showing good anti-tumor effects. This review introduces the properties of various nanoparticles including polymer nanoparticles, liposome nanoparticles, quantum dots, dendrimers, and gold nanoparticles and their applications in tumor tissues. In addition, the specific application of nanoparticle-based drug delivery for lung cancer therapy in preclinical studies and clinical trials is discussed.https://doi.org/10.1186/s12645-023-00174-xLung cancerNanoparticleImmune targeted therapyNanotherapy |
| spellingShingle | Yifan Liu Wenxu Cheng HongYi Xin Ran Liu Qinqi Wang Wenqi Cai Xiaochun Peng Fuyuan Yang HongWu Xin Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy Cancer Nanotechnology Lung cancer Nanoparticle Immune targeted therapy Nanotherapy |
| title | Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| title_full | Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| title_fullStr | Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| title_full_unstemmed | Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| title_short | Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| title_sort | nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy |
| topic | Lung cancer Nanoparticle Immune targeted therapy Nanotherapy |
| url | https://doi.org/10.1186/s12645-023-00174-x |
| work_keys_str_mv | AT yifanliu nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT wenxucheng nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT hongyixin nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT ranliu nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT qinqiwang nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT wenqicai nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT xiaochunpeng nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT fuyuanyang nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy AT hongwuxin nanoparticlesadvancedfrompreclinicalstudiestoclinicaltrialsforlungcancertherapy |